Developing new orphan therapies, increasing access to existing life-saving treatments, and lowering costs is a moral imperative. However, major challenges remain for the rare disease community to achieve these goals.
DPHARM is the first event in the United States to question how we can disrupt the way clinical research gets done to reduce the burden to patients and physicians. DPHARM [….]
TYSONS CORNER, Va. (PRWEB) September 20, 2021 — Clinical trials of new drugs and treatments have a high failure rate. Better planning and technology-aided communication, says Dr. Harsha Rajasimha of Jeeva Informatics, can significantly reduce the number of participants who drop out, thus improving the chances of success—for the trials and the therapeutic product itself.
Over the years, minority input in the clinical development of life-saving drugs has been lacking, particularly when it comes to clinical trial participation. That has led to disparities in the efficacy of medications when taken by minority
LucasPye Bio, a Philadelphia biologics contract development and manufacturing organization, has formed a partnership with Africa-based genomics company IndyGeneUS AI aimed at advancing targeted therapeutics focused on health disparities.
Windtree Therapeutics Chief Executive Officer Craig Fraser called 2020 a transformative and productive year for the Bucks County company focused on the development of life-saving therapeutics for acute cardiovascular and pulmonary disorders. Despite cardiovascular disease being the number-one cause of global death, Fraser said few companies are pouring their resources into addressing the disease, especially when compared to oncology research. Windtree’s lead clinical program istaroxime is a novel therapeutic aimed at heart failure, the number one reason for hospitalization in the United States.
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373, the company’s COVID-19 vaccine candidate. Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax’ Phase 2b trial in South Africa and its pivotal Phase 3 trial in the United Kingdom.
Launched in New York, two-year-old data science company DrugViu, which has created a comprehensive and diverse Real-World Evidence Platform for immunological research, will relocate its headquarters to Northern Virginia.
In recognition of Rare Disease Day 2021, Jeeva Informatics (Jeeva) brought together a panel of experts to discuss the importance of transforming the clinical trial process for rare diseases. The panel included Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases; Thomas Lester, Former Executive Director, Audentes Therapeutics; Scott Schliebner, Senior Vice President, Scientific Affairs & Therapeutic Expertise, PRA Health Sciences; and Dr. Eric Sid, Program Director, National Center for Advancing Translational Science, Office of Rare Disease Research, (NCATS)/NIH.
Heather Mudrick Joins Workforce Genetics to Lead Clinical Search Practice
